The association of serum prolidase activity with the presence and severity of coronary artery disease
暂无分享,去创建一个
O. Erel | N. Aksoy | M. Gur | A. R. Ocak | A. Yildiz | R. Demirbağ | R. Yılmaz | I. H. Altıparmak | Selahattin Akyol
[1] N. Aksoy,et al. Serum prolidase activity in patients with hypertension and its relation with left ventricular hypertrophy. , 2007, Clinical biochemistry.
[2] M. Manabe,et al. Prolidase Isoenzymes in the Rat: Their Organ Distribution, Developmental Change and Specific Inhibitors , 2007, Pediatric Research.
[3] H. Çelik,et al. Serum prolidase activity and oxidative status in Helicobacter pylori infection. , 2007, Clinical biochemistry.
[4] H. Çelik,et al. Increased oxidative stress and its relation with collagen metabolism in knee osteoarthritis , 2007, Rheumatology International.
[5] O. Erel,et al. Paraoxonase and arylesterase activities in coronary artery disease , 2006, European journal of clinical investigation.
[6] M. Wojtukiewicz,et al. Enhanced prolidase activity and decreased collagen content in breast cancer tissue , 2006, International journal of experimental pathology.
[7] A. V. Rij,et al. Elevated Plasma Active Matrix Metalloproteinase-9 Level Is Associated With Coronary Artery In-Stent Restenosis , 2006, Arteriosclerosis, thrombosis, and vascular biology.
[8] D. Messadi,et al. Elevated prolidase activity in keloids: correlation with type I collagen turnover , 2006, The British journal of dermatology.
[9] V. Chopra,et al. Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction. , 2006, American heart journal.
[10] S. Unver,et al. The Role of Prolidase Activity in the Diagnosis of Uremic Bone Disease , 2006, Renal failure.
[11] R. Schnabel,et al. Prognostic value of tissue inhibitor of metalloproteinase-1 for cardiovascular death among patients with cardiovascular disease: results from the AtheroGene study. , 2006, European heart journal.
[12] H. Leu,et al. Plasma matrix metalloproteinase‐3 level is an independent prognostic factor in stable coronary artery disease , 2005, European journal of clinical investigation.
[13] Reiko Ohmori,et al. Plasma matrix metalloproteinase-8 concentrations are associated with the presence and severity of coronary artery disease. , 2005, Circulation journal : official journal of the Japanese Circulation Society.
[14] G. Lip,et al. Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease. , 2005, The American journal of cardiology.
[15] D. Brieger,et al. Elevated circulating levels of matrix metalloproteinase‐9 and ‐2 in patients with symptomatic coronary artery disease , 2005, Internal medicine journal.
[16] A. Surazynski,et al. Differential effects of echistatin and thrombin on collagen production and prolidase activity in human dermal fibroblasts and their possible implication in beta1-integrin-mediated signaling. , 2005, Pharmacological research.
[17] Reiko Ohmori,et al. Levels of matrix metalloproteinase-1 in patients with and without coronary artery disease and relation to complex and noncomplex coronary plaques. , 2005, The American journal of cardiology.
[18] J. Steghens,et al. Plasma lipid hydroperoxides measurement by an automated xylenol orange method. , 2004, Analytical biochemistry.
[19] A. Surazynski,et al. Phosphorylation of prolidase increases the enzyme activity , 2001, Molecular and Cellular Biochemistry.
[20] H. Lijnen. Metalloproteinases in Development and Progression of Vascular Disease , 2003, Pathophysiology of Haemostasis and Thrombosis.
[21] P. Giral,et al. Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 as potential markers of carotid atherosclerosis in infraclinical hyperlipidemia. , 2003, Atherosclerosis.
[22] A. Erbaǧci,et al. Serum prolidase activity as a marker of osteoporosis in type 2 diabetes mellitus. , 2002, Clinical biochemistry.
[23] H. Ishizaka,et al. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. , 2001, American heart journal.
[24] F. Spinale,et al. Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. , 1998, Circulation.
[25] P. Shah,et al. Role of inflammation and metalloproteinases in plaque disruption and thrombosis , 1998, Vascular medicine.
[26] A. Girotti. Lipid hydroperoxide generation, turnover, and effector action in biological systems. , 1998, Journal of lipid research.
[27] A. Henney,et al. Matrix metalloproteinases: implication in vascular matrix remodelling during atherogenesis. , 1998, Clinical science.
[28] J. Phang,et al. Prolidase activity in fibroblasts is regulated by interaction of extracellular matrix with cell surface integrin receptors , 1997, Journal of cellular biochemistry.
[29] M. Lewis,et al. Prolidase deficiency and systemic lupus erythematosus , 1997, Archives of disease in childhood.
[30] T. Oono,et al. Localization of prolidase gene expression in scar tissue using in situ hybridization. , 1996, Journal of dermatological science.
[31] P. Libby,et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. , 1994, The Journal of clinical investigation.
[32] G. Cetta,et al. Prolidase deficiency: biochemical study of erythrocyte and skin fibroblast prolidase activity in Italian patients. , 1994, Haematologica.
[33] A. Newby,et al. Extracellular matrix degrading metalloproteinases in the pathogenesis of arteriosclerosis. , 1994, Basic research in cardiology.
[34] C. Cross,et al. Antioxidant protection against hypochlorous acid in human plasma. , 1993, The Journal of laboratory and clinical medicine.
[35] I. Myara,et al. Plasma prolidase activity: a possible index of collagen catabolism in chronic liver disease. , 1984, Clinical chemistry.
[36] B. Kishore,et al. Prolidase and prolinase activities in the erythrocytes of patients with chronic uremia. , 1983, Nephron.
[37] G. Gensini,et al. A more meaningful scoring system for determining the severity of coronary heart disease. , 1983, The American journal of cardiology.
[38] I. Myara,et al. Optimal conditions for prolidase assay by proline colorimetric determination: application to iminodipeptiduria. , 1982, Clinica chimica acta; international journal of clinical chemistry.
[39] G. Ellman,et al. Tissue sulfhydryl groups. , 1959, Archives of biochemistry and biophysics.
[40] F. Chinard. Photometric estimation of proline and ornithine. , 1952, The Journal of biological chemistry.